Clinical Trial Update: Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating two doses of EVP-6124 in Alzheimer's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Alzheimer's Disease, Dementia | Phase 3 | Status: TERMINATED